Rox Medical Inc. Initiates First Commercial Activities in Germany of Minimally Invasive CO2UPLER Implant in Conjunction with a Phase IV Registry for Patients with Chronic Obstructive Pulmonary Disease (COPD)
12/2/2010 11:24:11 AM
SAN CLEMENTE, Calif.--(BUSINESS WIRE)--ROX Medical, INC., a world leader in the development of a unique minimally invasive medical device approach for the treatment of advanced COPD, today announced the start of commercial sales in Germany of the company’s ROX® CO2UPLER. The Company's commercial activities incorporate a patient registry to capture physician and patient experiences in an effort to expand the understanding of clinical outcomes associated with the procedure. The purpose of the registry is to benchmark experiences with the ultimate goal of establishing the ROX® FLO2W procedure as a standard of care for hypoxic COPD patients.